

WEST PHARMACEUTICAL SERVICES INC  
Form 8-K  
May 13, 2014

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported) – May 13, 2014  
WEST PHARMACEUTICAL SERVICES, INC.  
(Exact name of registrant as specified in its charter)

|                                                                   |                                        |                                                        |
|-------------------------------------------------------------------|----------------------------------------|--------------------------------------------------------|
| Pennsylvania<br>(State or other jurisdiction<br>of Incorporation) | 1-8036<br><br>(Commission File Number) | 23-1210010<br><br>(IRS Employer<br>Identification No.) |
|-------------------------------------------------------------------|----------------------------------------|--------------------------------------------------------|

|                                                                                       |                              |
|---------------------------------------------------------------------------------------|------------------------------|
| 530 Herman O. West Drive, Exton,<br>PA<br>(Address of principal executive<br>offices) | 19341-0645<br><br>(Zip Code) |
|---------------------------------------------------------------------------------------|------------------------------|

Registrant's telephone number, including area code: 610-594-2900

Not Applicable  
(Former name or address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 7.01 Regulation FD Disclosure.

On May 13, 2014, our management will present at the Bank of America Merrill Lynch 2014 Healthcare Conference in Las Vegas, Nevada at 5:00 PM Pacific Time.

A copy of the Company's presentation materials from the conference will be available for 30 days through the Investors link at the Company's website, <http://www.westpharma.com>, and is also attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (Exchange Act) or otherwise subject to the liabilities of that section, nor will it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referencing in such filing.

Item 9.01 Financial Statements and Exhibits.

- (d) Exhibits  
Exhibit 99.1 West Pharmaceutical Services, Inc. Investor Presentation.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

WEST PHARMACEUTICAL SERVICES,  
INC.

/s/ John R. Gailey III  
John R. Gailey III, Senior Vice President,  
General Counsel and Chief Compliance  
Officer

May 13, 2014

EXHIBIT INDEX

| Exhibit No. | Description                                               |
|-------------|-----------------------------------------------------------|
| 99.1        | West Pharmaceutical Services, Inc. Investor Presentation. |

4